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ABSTRACT 
 
The discovery of oncogenes and signal transduction pathways important for mitogenesis has triggered the development of target-
specific small molecule anti-cancer compounds. As exemplified by imatinib (Gleevec), a specific inhibitor of the Chronic Myeloid 
Leukemia (CML)-associated Bcr-Abl kinase, these agents promise impressive activity in clinical trials, with low levels of clinical toxicity. 
However, such therapy is susceptible to the emergence of drug resistance due to amino acid substitutions in the target protein. Defining 
the spectrum of such mutations is important for patient monitoring and the design of next-generation inhibitors. Using imatinib and 
BCR/ABL as a paradigm for a drug-target pair, we recently reported a retroviral vector-based screening strategy to identify the 
spectrum of resistance-conferring mutations. Here we provide a detailed methodology for the screen, which can be generally applied to 
any drug-target pair. 
 
 
INTRODUCTION 
 
Novel discoveries in cancer biology have provided the 
opportunity to design target-specific anti-cancer agents and 
fostered rapid advancements in drug development. The current 
focus is the design of molecules with high selectivity against 
specific proteins in malignant cells, to insure a high therapeutic 
index with minimal side effects. The unprecedented success of 
the BCR/ABL tyrosine kinase inhibitor imatinib 
(STI571/Gleevec, Novartis) in the treatment of chronic 
myeloid leukemia (CML) has inspired great expectations for this 
approach (1, 2). Complete hematologic responses to imatinib 
are seen in >95% of CML patients and a major cytogenetic 
response in >60% of patients treated in the chronic phase of 
the disease (3, 4). However, highly specific protein inhibition 
brings with it a critical problem: protein targets develop escape 
mutations leading to drug resistance. In fact, virtually all 
patients with advanced stages of CML ultimately manifest 
imatinib resistance (5-7), and it is expected that other protein 
targets will evolve drug resistant forms as well in response to 
therapy. The identification of these mutant forms is essential 
for the design of more robust next generation therapies, and 
may ultimately lead to molecular cocktails designed to 
circumvent resistance. 
 
In previous work, we reported the results of a screen involving 
random mutagenesis of BCR/ABL to reveal the spectrum of Azam et al.    
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mutations conferring resistance to imatinib. The results not 
only identified the mutants critical for clinical disease relapse, 
but also shed light on the mechanism of auto-inhibition of the 
Abl kinase (8). Here we provide additional methodologic detail 
to enable a broader application of this screening strategy to 
additional drug-target pairs. 
Fig. 1: General strategy for a drug resistance screen of a drug target pair. 
 
MATERIALS AND METHODS 
 
Overview 
 
To identify a wide spectrum of drug resistance conferring 
mutations, we generated a high complexity library of 
mutagenized BCR-ABL cDNA in a retroviral vector and 
introduced this into cells by retroviral transduction. We then 
selected for surviving drug-resistant clones, recovered 
plasmid DNA or PCR amplicons, and analyzed their 
sequence for the presence of mutations. To verify that the 
observed mutations were the basis of drug resistance, we 
regenerated each mutation separately by site-directed 
mutagenesis of native BCR-ABL, and reintroduced them 
into cells. 
 
Briefly, the strategy is as follows (see Fig. 1): 
 
•  Clone the target cDNA into a retroviral vector. 
•  Propagate the vector in bacteria deficient in DNA repair 
mechanisms, creating an exhaustive library of mutations 
in the target gene. 
 
•  Transfect/infect drug-sensitive cells with the mutated 
vector and disperse in soft agar in the presence of drug.  Retroviral construct, library generation and 
mutagenesis  •  Isolate resistant colonies, recover the target cDNA, and 
sequence to identify mutations.   
Full length BCR-ABL cDNA was cloned into the EcoRI site of 
the pEYK3.1 retroviral vector (8), generating pEYKBA. Using 
XL-1 Red competent E.coli cells (Stratagene) deficient in DNA 
repair mechanisms, 1ug of DNA was transformed according to 
the manufacturer’s recommendations. More specifically, 10-50 ng 
of DNA (any more than 100 ng decreases transformation 
efficiency) was mixed with 100 µl of competent cells in a pre-
chilled polypropylene tube and incubated on ice for 30 min, 
gently swirling every 2 min. The tube was then immersed in a 
water bath at 42°C for a heat shock of 45 seconds and incubated 
on ice for 2 min. Next, 1 ml of SOC medium (2.0% tryptone, 
0.5% yeast extract, 0.05% NaCl, 10 mM MgCl2, 10 mM MgSO4, 
and 0.4% D-glucose) was added and the tube incubated at 37°C 
while shaking at 225-250 rpm for 90 min. The cells were then 
plated onto 4-8 LB-agar/zeocin plates (25 ug/ml Zeocin from 
Invitrogen) and incubated at 37°C. After 18-24 hrs, the colonies 
 
The resistant phenotype of the mutations is then confirmed 
as follows: 
 
•  Mutations are recreated in the native cDNA by site 
directed mutagenesis. 
•  Cells are transfected/infected and grown in the presence 
of drug. 
•  Resistance is measured by proliferation assays and/or 
immunoblotting. 
•  Mutations can be analyzed for their structural 
consequences by mapping onto a model of the protein 
crystal structure. 
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  were collected by scraping the plates with a sterile plate scraper 
and plasmid DNA was isolated using the Qiagen Miniprep Kit. 
At this stage, the heterogeneity of mutations in each plasmid can 
be roughly assessed by restriction digest with a frequent cutter 
such as Sau3A1 or Taq1.  
Sequencing of PCR products 
 
Specific sub-regions of BCR-ABL cDNA were amplified by PCR 
using the following primers:  
   
SH3-SH2 (f) 5'-CTCCACACTGTCCACAGCATTCC-3';  
SH3-SH2 (r) 5'-CTGTCATCAACCTGCTCAGGC-3';  
SH2-kinase (f) 5'-CGTGAGAGTGAGAGCAGTCC-3';  
SH2-kinase (r) 5'-GCAGCTCTCCTGGAGGTCCTCG-3'.  
Production of retroviral supernatants 
 
One day before transfection, 5 x 105 HEK 293T cells were plated 
onto 60 mm dishes in DMEM containing 10% FCS, pen/strep 
and 2 mM L-glutamine. The medium was replaced the next day 
and cells transfected with either the mutagenized pEYKBA 
library or the native pEYKBA plasmid in the presence of 
FuGENE6 (Roche) and a 1:1 ratio of retroviral construct to 
retroviral packaging construct pCL-eco (8). The medium was 
changed and viral supernatant collected and filtered through a 
0.45  µm Acrodisc filter 16 hr and 30 hr respectively post 
transfection. 
 
The PCR products were then sequenced and analyzed by 
DNASTAR II. 
 
Provirus rescue from genomic DNA 
 
Provirus was extracted from genomic DNA as described 
previously (9). Briefly, 10 µg of genomic DNA were digested 
with NotI to release the provirus. The provirus was then self-
ligated under dilute conditions (100 µl of reaction volume per 
1 µg of genomic DNA), phenol/chloroformed extracted and 
ethanol precipitated. TOP10 competent cells (Invitrogen) 
were transformed with the ligation and plated onto LB-
agar/zeocin plates. Colonies were picked, expanded in liquid 
culture overnight, and the plasmid DNA isolated. The isolated 
clones were reintroduced into BaF3 cells and plated in the 
presence of imatinib to verify drug resistance. Finally, the drug 
resistant clones were sequenced to analyze their mutations.  
 
Retroviral transduction 
 
The BaF3 cell line is a murine pro B cell line that is dependent on 
Interleukin-3 (IL-3) for growth. Ectopic expression of 
constitutive tyrosine kinases such as BCR-ABL render the BaF3 
cells IL-3 independent (10). BaF3 cells have a low intrinsic 
background of spontaneous transformation. BaF3 cells were 
grown in RPMI medium containing 10% FCS, pen/strep, 2 mM 
L-glutamine, and 5% WEHI-3B conditioned medium (a source 
of IL-3). With a range of 105  - 108 infectious units/ml of 
retroviral supernatant, we infected 1x106 BaF3 cells along with 8 
µg/ml polybrene (Sigma) and centrifuged for 90 min at 2500 
rpm, 33°C in a Sorvall RT 6000 table centrifuge. Following an 
incubation of 14-16 hr at 37°C, 5% CO2, selection for Imatinib 
resistant cells was initiated by removal of IL-3 from the medium 
by washing the cells in WEHI-3B free RPMI/10% FCS. We have 
employed low viral transduction efficiency (e.g. 20-30%) in order 
to avoid inducing a drug resistant phenotype due to multiple 
proviral integrations. 
 
Site-directed mutagenesis 
 
Site-directed mutagenesis was performed on the native 
pEYKBA plasmid using the Quickchange Mutagenesis Kit 
from Strategene and oligonucleotides that were designed to 
create the point mutations found in our screen. Each mutant 
created was confirmed by sequencing. 
 
  Cell viability assay to determine IC50 
Screening for resistance   
104 BaF3 cells expressing mutant pEYKBA were plated into 
each well of a 96-well plate in RPMI/10% FCS. Imatinib was 
added to the media in increasing concentrations (final 
concentration: 0, 1, 3, 5, 10, and 20 µM) across the plate and 
cells incubated for 60 hr. Cell viability was assessed with the 
WST-1 reagent (Roche) according to the manufacturer’s 
recommendations and read with an ELISA plate reader at 450 
nm. All assays were performed in quadruplicate and readings 
averaged and plotted against imatinib concentration as a best 
fit sigmoidal curve by using a nonlinear curve-fitting algorithm 
(Origin 7.0, Origin Lab, Northhampton, MA). The drug 
concentration resulting in 50% cell viability was scored as the 
Cellular IC50.  
 
To select for drug resistant BCR-ABL mutants, the infected cells 
were plated in soft agar containing varying concentrations of 
imatinib. More specifically, 8 x 106 cells were mixed with 28.8 ml 
RPMI, 9.6 ml FCS, 9.6 ml of 1.2% Bacto-agar (made in PBS, 
autoclaved and cooled to 42°C), and supplemented with 
concentrations of 5 - 10 µM imatinib. The mix was then plated, 3 
ml/well, into 6-well plates and incubated at 37°C, 5% CO2, for 
10 days before single colonies were picked and expanded 
separately in 3 ml RPMI/10% FCS in the presence of 5 - 10 µM 
imatinib. Following expansion, genomic DNA was isolated using 
the Qiagen DNeasy Kit and sequenced. Two approaches for 
sequencing were compared. Both strategies are described below. 
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RESULTS AND DISCUSSION 
 
We have developed a general method to identify the spectrum of 
amino acid substitutions in a target oncoprotein that confer 
resistance to a target-directed small molecule anti-cancer agent. 
Our strategy was to first generate random point mutations in the 
target oncogene, and thereby create a complex library with single 
amino acid substitutions in every residue of the oncoprotein 
product. Next, we introduced this library into cells susceptible to 
transformation, and selected for the transformed phenotype in 
the presence of drug. We then isolated the resistant cells and 
sequenced the mutated target gene to reveal putative mutations. 
To validate the resistant phenotype of each candidate mutation, 
we recreated each mutation de-novo by site-directed mutagenesis, 
infected fresh cells, and confirmed their drug-resistant 
transformation. 
 
We have used this strategy to define the spectrum of mutations 
in BCR-ABL that confer resistance to imatinib. We identified 112 
such amino acid substitutions—a catalogue of mutations that is 
more comprehensive than discovered by clinical surveys to date. 
In addition to all major mutations detected in patients, we 
identified novel substitutions of residues both within and beyond 
the kinase domain (3). Some of the novel mutants discovered in 
our screen have since been found in patients (5-7), demonstrating 
the ability of the screen to anticipate clinically problematic drug 
resistance.  
 
Random mutagenesis offers several advantages over the more 
popular PCR-based mutagenesis methods. Larger DNA 
fragments can be mutagenised in a relatively simple plasmid 
propagation procedure, while larger fragments are a challenge for 
PCR amplification. PCR mutagenesis also requires additional 
cumbersome and time-consuming steps to subclone the 
mutagenised DNA into an expression vector. We have screened 
8 million cells with retroviral transduction efficiency of 20%, 
which should give rise to 1.6 million independent clones of cells 
containing mutant Bcr-Abl. On the basis of this calculation each 
mutant plasmid is represented approximately 160 times in the 
screen. 
 
During our screen, we found that it is important to avoid bulk 
culture conditions in which cells harboring different mutations 
are pooled together and allowed to expand in liquid culture, since 
this can lead to clonal dominance of a few highly drug-resistant 
variants. When we initially selected for imatinib-resistance of 
mutagenized BCR/ABL in bulk liquid culture, we found only 4 
mutant forms that were represented multiple times within the 
first 100 isolates we sequenced. In contrast, we identified over 
100 mutants when we selected for outgrowth of clones in the 
soft agar colony-forming assay. Some slow-growing clones with 
more modest degrees of drug resistance could not have been 
recovered using bulk culture. We thus recommend to avoid any 
growth or selection in bulk, either within the bacterial or 
mammalian cell cultures. For that reason, we attempted to 
minimize any incubation periods where cells are pooled together. 
After retroviral infection, we maintained the cells in bulk culture 
prior to selection for only 14 to 16 hours, after which we 
performed combined IL-3 withdrawal and drug selection in soft 
agar. This provided for tight selection of individual clones and 
prevented clonal dominance of liquid cultures. If the cells used 
for drug screening do not form colonies in soft agar they can be 
selected in a similar clonal manner by limiting dilution in 96 well 
plates. 
 
Once candidate mutations are isolated, it is imperative to confirm 
their ability to confer resistance in isolation, since some plasmids 
may house multiple mutations or false-positive amino acid 
substitutions that co-exist with other true resistant variants. It is 
also important to recognize that some classes of mutation, like 
allosteric variants occurring outside the catalytic site of a target 
enzyme, might generate subtle degrees of drug resistance that 
while not clinically meaningful can provide invaluable insights 
into enzyme regulation. For our BCR-ABL screen, we recreated a 
majority of the mutations using site directed mutagenesis of the 
native target kinase, and introduced the mutants into fresh cells. 
These cells were then grown in the presence of drug and assessed 
for their level of drug resistance. We tested cell viability in varying 
drug concentrations to determine individual mutant's IC50, and 
assessed BCR-ABL enzymatic activity by determining the degree 
of autophosphorylation by Western blot analysis. We validated 
the resistance profile for the vast majority of candidate mutations 
recovered in our primary screen, and found that less than 10% of 
the mutations were false positives (8). 
 
Given the increasing trend toward development of target specific 
small molecule inhibitors for cancer therapy, it is essential to 
define the spectrum of clinically problematic resistance-
conferring mutations to newly developed drugs. This will allow 
patient monitoring for early detection of drug resistance, and the 
design of more robust next-generation therapies. We have 
employed our screening strategy to identify mutations in the beta 
subunit of the farnesyl protein transferase that confer resistance 
to farnesyl transferase inhibitors, an unrelated class of anticancer 
compounds (Raz et al., unpublished). Thus we believe that the 
screening method will be generally applicable to a broad range of 
anti-cancer or anti-proliferative compounds, and should also be 
effective at defining drug resistant variants in viral, bacterial, and 
fungal targets using a similar combination of bacterial 
mutagenesis, cell selection, plasmid rescue, and sequencing. 
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PROTOCOLS 
 
Mutagenesis and library construction 
 
XL-1 Red transformation 
 
Thaw 100 µl XL-1 Red competent E-Coli (Stratagene), in a polypropylene tube on ice. 
Gently mix in 10-50ng plasmid DNA. 
Incubate on ice for 30 min, gently swirling every two minutes. 
Immerse the tube in a 42°C bath for 45 sec and immediately incubate on ice for 2 min. 
Add 1ml SOC medium and incubate at 37°C shaking at 225-250rpm for 90 min. 
Plate the cells on 4 to 8 Zeocin plates (25 µg Zeocin per ml of LB-Agar) and incubate at 37°C for 18-24 hours. 
Collect the bacterial colonies by scraping the plates with sterile plate scrapers (pooling together all colonies on the plate). 
Isolate DNA by maxiprep using Qiagen kit according to manufacturer’s instructions (miniprep can also be used). 
SOC medium 
2% tryptone 
0.5% yeast extract 
0.05% NaCl 
10mM MgCl2 
10mM MgSO4 
0.4% D-glucose 
 
Production of retroviral supernatants 
 
Day 0 - Plate 5 x 105 HEK 293T cells in DMEM (10% FCS, 50 u/ml penicillin, 50 µg/ml streptomycin, 2 mM glutamine) in a 60mm 
plate. Incubate at 37°C, 5% CO2 overnight. 
Day 1 - Mix together in order: DME up to 100 µl, mutagenized retroviral plasmid DNA (1 µg), PCL/Eco retroviral packaging 
construct (1 µg), and 6 µl Fugene6 (Roche) and incubate at room temperature for 15 min. 
Replace the medium of the HEK 293T cells carefully (to prevent them from lifting off the plate). 
Pipette the 100 µl of the Fugene6 mixture onto the plate and incubate at 37°C, 5% CO2.  
Day 2 - Replace the medium 16-24 hours after transfection and incubate for an additional 15-24 hours. 
Day 3 - Collect and filter the supernatant through a 0.45 µm filter (Acrodisc).  
Use immediately for infection (or freeze at -80°C). 
 
Retroviral Infection 
 
Retroviral supernatant should be titered to optimize infection efficiency. In general: 
1.  Plate 2.5 x 105 of the target cells (BaF3 in our case) in each well of a 6 well plate using fresh medium (if adherent cells are used they 
should be allowed to adhere overnight before infection). 
2.  Calculate the desired concentration of the filtered supernatant and add to each well (usually between 400 - 1000 µl). 
3.  Centrifuge at 2500 rpm for 90 min at 33°C in a Sorvall RT6000 table centrifuge.  
4.  Apply appropriate selection 16 hours after infection. For BaF3 cells remove medium, wash with PBS and add RPMI (with out 
WeHi-3b). Incubate at 37°C, 5% CO2 for an additional 14 hours. – This step is not necessary. Alternatively skip directly to drug 
resistance selection (16 hours after infection). 
 
Drug resistance selection 
 
1.  Mix together 8 x 106 infected cells in 28.8 ml RPMI with 9.6 ml FCS, and the appropriate drug concentration. 
2.  Add 9.6 ml of 1.2% Bacto-agar (made in PBS, autoclaved, and cooled to 42°C). 
3.  Immediately plate 3ml in each well of a 6 well plate, filling 16 wells all together. 
4.  Incubate the cells for 10 -14 days at 37°C, 5% CO2.  
5.  Pluck single colonies and expand in 3ml RPMI (10%FCS) in the presence of drug. 
6.  Once the cells are confluent use the DNeasy Kit (Qiagen) to isolate genomic DNA according to manufacturer’s instructions. 
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7.  Amplify the mutagenized DNA using appropriate primers and sequence. 
 
Resistance testing 
 
IC50 cell viability assay  
 
1.  Plate 0.5-1 x 104 cells expressing the mutant construct in each well of a 96 well plate using 50 µl of the appropriate medium. 
2.  Add 50 µl cell medium with a 2X drug concentration to each well. Use a range of concentrations that will span from weak to 
strong target inhibition (for example 0, 1, 3, 5, 10, and 20 µM in the case of Imatinib). Keep one well with no cells to use as 
reference for the ELISA readout. 
3.  Allow the cells to incubate in drug for 36-60 hours. 
4.  Add the WST-1 reagent (Roche) to each well according to manufacturer’s instructions. 
5.  Read using an ELISA reader at 450nm. 